Please Scroll Down to See Forums Below
napsgear
genezapharmateuticals
domestic-supply
puritysourcelabs
UGL OZ
UGFREAK
napsgeargenezapharmateuticals domestic-supplypuritysourcelabsUGL OZUGFREAK

Aifm Rash Poll

Did you get a rash from AIFM?

  • YES

    Votes: 21 36.8%
  • NO

    Votes: 31 54.4%
  • No, but I got something else......what is it?

    Votes: 4 7.0%

  • Total voters
    57
Status
Not open for further replies.
:LockMe!:

What purpose does this thread serve? Any poll of this type won't yield useful information. What we have instead is people who have earned our respect bickering in a self-indulgant manner. What happened to the need to control information responsibly? I say we use a brain trust of interested members on this board to review the available data and achieve a consensus of AIFM's worthiness. As AF's integrity is not an issue, the only outcome of this would be to demonstrate what so many accomplished individuals are doing here in the first place. :P
 
macrophage69alpha said:
ALL Aromatase inhibitor reduce aromatase activity in the brain. Especially when injected or distributed by silastic capsule directly into the brain.

Yes aromasin binds to the AR with similar affinity .2% of DHT. This only has any meaning if you have no androgens.

these things were already pointed out to anthony and mr.x prior, though they have conveniently forgotten them.

Sorry to keep bumping this but...

When you mention injecting or silastic capsules, you are referring to the delivery method used in the animal studies, right?
As far as reduced cognitive ability, could this be an issue with any AI if taken in high enough quantities? Is there a tissue concentration issue to be considered with transdermal administration of any AI including AIFM?
 
YES

YES- absolutely this is why leto causes sexual dysfunction even below treatment doses- imagine taking that amount for an extended period and not being on cycle- yes complete estrogen deprivation will have negative effects on cognition.

YES- though limiting aromatase in fat tissue is not really a bad thing. Tissue concentration of ATD and/or local aromatase suppresion may be an factor in allergy response. This is being looked at. Even though the percentage is small, reducing it even slightly is of course the goal.
 
This isn't going to go away is it? We might as well get some answers with evidence to substantiate the claims being made.
 
nuevo laredo said:
Sorry to keep bumping this but...

When you mention injecting or silastic capsules, you are referring to the delivery method used in the animal studies, right?
As far as reduced cognitive ability, could this be an issue with any AI if taken in high enough quantities? Is there a tissue concentration issue to be considered with transdermal administration of any AI including AIFM?

The man who actually suffered this blames the transdermal delivery method as being the factor that when combined with an AI caused his problem.

IT is his contention, and I think a well thought out one, that the sustained delivery and lack of peaks/vallies that 1x a day oral administration would provide.

Again, he thinks this is because he used a transdermal AI, not just an AI, which he'd had success with in the past.
 
anthony roberts said:
The man who actually suffered this blames the transdermal delivery method as being the factor that when combined with an AI caused his problem.

IT is his contention, and I think a well thought out one, that the sustained delivery and lack of peaks/vallies that 1x a day oral administration would provide.

Again, he thinks this is because he used a transdermal AI, not just an AI, which he'd had success with in the past.

This whole debate has been interesting, but I think there is a problem with that guys' theory.

If i read correctly, he believes it was the sustained blood levels that the transdermal offers that caused his problems because of the lack of peaks and troughs in blood levels, so if this were the case, wouldn't armidex have the same brain aromatisation problems because its half life is approx 50 hours?
Or perhaps it wouldn't have the problem because it is not a suicidal aromatase inhibitor?
 
JohnnyWest said:
This whole debate has been interesting, but I think there is a problem with that guys' theory.

If i read correctly, he believes it was the sustained blood levels that the transdermal offers that caused his problems because of the lack of peaks and troughs in blood levels, so if this were the case, wouldn't armidex have the same brain aromatisation problems because its half life is approx 50 hours?
Or perhaps it wouldn't have the problem because it is not a suicidal aromatase inhibitor?

No...because it still has the peak, the onset and then decline....transdermals provide basically a sustained release of the drug that's unwavering...so...follow this guy's reasoning here...the HUGE half life plus the HUGE sustained delivery...allows no time when there isn't a dose of AI constantly killing aromatase...and that becomes dangerous, in his opinion, because there's no "let up" as with an oral...it just has a huge halflife and a really long sustained time release = recipe for disaster. NOW add in that ATD can have anti androgenic effects? I'd avoid it like crazy...
 
having actually spoken with triceptor and not just making things up. The extended use of high doses of any AI will have the same effect.

in triceptors case (the person that anthony does not actually care about but is trying to use his unfortunate situation to bolster his erroneous conclusions) he was using what he recconed to be 60mg per day DELIVERED of ATD. Thats 10-12 times the clinical suppression dose. He did this for 3-4 months without taking an AAS.

now it is anthony's contention that an individual taking a comparable amount of say letrozole (which would be more than 10mg per day) and not taking any AAS would not have similar problems.

since most guys on cycle get severe estrogen suppression with 2.5mg of letro ED, this assertion of his does not hold water.
 
anthony roberts said:
NOW add in that ATD can have anti androgenic effects? I'd avoid it like crazy...

then add to that list exemestane, which you seem to reccomend quite often, it has the same activity and binding affinity as ATD. Which is .2% of DHT. Its a non factor except in cell models and castrated animals. So in conditions that are androgen deprived where such weak binding would then become relevant.



btw- this has been explained to you over and over again anthony, one can only assume that your reposts of this erroneous information are intentional. Why exactly are you trying to mislead people?
 
Status
Not open for further replies.
Top Bottom